Products for Research Use Only
RegisterLogin

BGB-283

CAT: 0013-GTR19217396-02Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19217396-02Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BGB-283 (Lifirafenib, BGB283) is a potent pan RAF inhibitor of BRAF V600E, wt BRAF, CRAFY340/341D and wt ARAF (IC50=5-40 nM) ; inhibits recombinant BRAFV600E with IC50 of 23 nM; also inhibits EGFR and EGFR T790M/L858R with IC50 of 29 nM and 495 nM respectively; potently inhibits BRAF (V600E) -activated ERK phosphorylation and cell proliferation in vitro; shows tumor growth inhibition in both cell line-derived and primary human colorectal tumor xenografts bearing BRAF (V600E) mutation.Colon Cancer Preclinical.
CAS Number
1446090-77-2
Product Name Alternative
Lifirafenib | BGB 283 | BGB283
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 125 mg/mL
Smiles
[H][C@@]1 (C2=CC (OC3=C (CCC4=O) C (N4) =NC=C3) =CC=C2O[C@]51[H]) [C@@H]5C6=NC7=CC=C (C=C7N6) C (F) (F) F
Molecular Formula
C25H17F3N4O3
Molecular Weight
478.4227
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
1,8-Naphthyridin-2 (1H) -one, 5-[[ (1R,1aS,6bR) -1a,6b-dihydro-1-[6- (trifluoromethyl) -1H-benzimidazol-2-yl]-1H-cyclopropa[b]benzofuran-5-yl]oxy]-3,4-dihydro-, rel-

Chemical Information

Lifirafenib

Lifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor).

CAS Number1446090-77-2
PubChem CID89670174
IUPAC Name5-[[(1R,1aS,6bR)-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one
Molecular FormulaC25H17F3N4O3
Molecular Weight478.4
XLogP3.7
Topological Polar Surface Area89.1
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count3
Heavy Atom Count35
Formal Charge0
Complexity845
SMILES
C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)O[C@H]5[C@@H]4[C@@H]5C6=NC7=C(N6)C=C(C=C7)C(F)(F)F
InChI
InChI=1S/C25H17F3N4O3/c26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23/h1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33)/t20-,21-,22-/m0/s1
InChIKey
NGFFVZQXSRKHBM-FKBYEOEOSA-N
Chemical Structure
2D Structure
2D structure of Lifirafenib
CAS: 1446090-77-2
CID: 89670174
Formula: C25H17F3N4O3
MW: 478.4
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight478.4
XLogP33.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count3
Exact Mass478.12527490
Monoisotopic Mass478.12527490
Topological Polar Surface Area89.1 Ų
Heavy Atom Count35
Formal Charge0
Complexity845
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
GTR17967655Bgb Antibody
GTR19213376-01BGB 15025
GTR19206440-01BGB-102
GTR19259944-01BGB 15025
GTR19212155-01BGB-8035
GTR19194319ICR 283
GTR19198335-01GS 283
GTR19203632-01LLY-283
GTR19276174-01CRBN ligand-283
GTR19263361-01Antibacterial agent 283

Alternative Products

CatalogName
MBS131534BGB-283
MBS3841821-01Lifirafenib (BGB-283)
A16844-50Lifirafenib (BGB-283) 50mg
A16844-25Lifirafenib (BGB-283) 25mg
A16844-10Lifirafenib (BGB-283) 10mg
A16844-1Lifirafenib (BGB-283) 1mg
A16844-5Lifirafenib (BGB-283) 5mg
A16844-100Lifirafenib (BGB-283) 100mg
A16844-10mM-DLifirafenib (BGB-283) 10mM * 1mL in DMSO
HY-P991613BGB-A445

Popular Products